An interventional study of OnTrackCF in Cystic Fibrosis (CF) and Cystic Fibrosis - Complete, sponsored by Boston Children's Hospital. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Boston Children's Hospital · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Cystic Fibrosis by Boston Children's Hospital — 1 open to participants now, 1 under way, none of them phase 3. Cystic Fibrosis · Boston Children's Hospital.
Among the 16 studies in Cystic Fibrosis by Boston Children's Hospital, this one is one of 2 that started in 2025, is one of 7 with no phase, and was the 16th registered.
1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →1 of the 16 studies in Cystic Fibrosis by Boston Children's Hospital is open now, in 1 country. Recruiting first, the newest first:
Boston Children's Hospital · Sites in United States
Ages 6+
By country, each count listing its studies:
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 2 started in 2025.
This study's enrollment of 25 is below the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 29 across the 8 interventional studies, 108 across the 8 observational. Of the 14 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boston Children's Hospital is the lead sponsor of 609 studies on the registry; 148 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 19 (59%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Cystic Fibrosis by Boston Children's Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-site, nonrandomized study using mixed methods approach to evaluate the feasibility, acceptability, and user engagement of OnTrackCF for adults with Cystic Fibrosis (AWCF).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1) Any situation, in the opinion of the Investigator, that would compromise the safety of the patient or the quality of the data
Participants eligible to enroll will be provided with the OnTrackCF app (intervention), and will use the app for 4-12 weeks before completing feasibility measures and a qualitative interview.
Behavioral: OnTrackCF
OnTrackCF is a mHealth application co-developed with Upstream Dream. It is designed specifically to track and support adherence to CFTR modulator therapy. The app allows users to track their modulator intake and disease symptoms while supporting their adherence goals using Behavioral Change Techniques (BCTs) with empirical evidence of efficacy. The BCTs are administered primarily in the form of messages designed to deliver specific BCTs. The app sends up to 3 adherence support messages per day and provides detailed data to the user about their adherence levels, adherence goals, and disease symptoms. This process will continue until we reach an N=60 AWCF enrolled OR demonstrate that we have achieved 12 weeks of sustained user engagement with the app.
System Usability Survey (SUS)
By the last round of testing, the System Usability Survey (SUS) will have a median score of 75%.
Time frame: through study completion, projected to be 1 year
Intervention Feasibility and Acceptability (iFAQ)
By the last round of testing, the Intervention Feasibility and Acceptability (iFAQ) OnTrackCF scales (Engagement, Feasibility, Acceptability, Usefulness, and Satisfaction) will each have a median score of ≥4 (out of 5).
Time frame: through study completion, projected to be 1 year
Onboarding Completion
By the last round of testing, 90% of participants will complete the app onboarding process.
Time frame: through study completion, projected to be 1 year
Engagement with app features
By the last round of testing, 70% of onboarded participants will engage with at least one app feature at least once during each week of their study period.
Time frame: through study completion, projected to be 1 year
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Nov 2025 to primary completion in Sep 2026, 9 months.
Of 214 non-industry interventional studies with no phase under Cystic Fibrosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's 9 months is below that.
Counting every sponsor, half of 229 studies reached it within 24 months; a quarter within 12 and three quarters within 48.
Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Sep 2026, on Oct 27, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.